Bristol-Myers Squibb has discontinued development of BMS-986094 (INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C. This decision was made based on safety concerns from the ongoing assessment of patients in a Phase II study. An initial case of heart failure resulted in the death of a patient. The FDA subsequently placed the compound on clinical hold.   The company will take a $1.8 billion writedown related to the cancellation. Th...